Related Experiment Video

Updated: Dec 19, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

945

Regulation of PD-1 in T cells for cancer immunotherapy

Xibao Yu1, Rili Gao2, Yangqiu Li2

  • 1Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, Jinan University, Guangzhou, 510632, China; Department of Experimental Research, Sun Yat-sen University Cancer Center, State Key Laboratory Oncology in South China, Guangzhou, 510060, China.

European Journal of Pharmacology
|June 5, 2020
PubMed

Insights

Understanding programmed cell-death protein 1 (PD-1) regulation is key to overcoming cancer immune escape. This review details how PD-1 and its ligand PD-L1 impact T cell exhaustion and cancer treatment.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Cancer immune escape is a major challenge in immuno-oncology.
  • Cancer cells evade T cell attacks via inhibitory receptors like programmed cell-death protein 1 (PD-1) and its ligand PD-L1.
  • PD-1/PD-L1 interactions lead to T cell exhaustion and reduced anti-cancer immunity.

Purpose of the Study:

  • To review the molecular mechanisms regulating PD-1.
  • To elucidate how PD-1 regulation impacts T cell exhaustion.
  • To inform strategies for improving cancer immunotherapy.

Main Methods:

  • Literature review of recent studies on PD-1 regulation.
  • Analysis of molecular mechanisms including gene transcription, post-transcriptional, and post-translational modifications.
  • Focus on PD-1 regulation within T cells.

Main Results:

  • PD-1 regulation occurs at multiple molecular levels: transcriptional, post-transcriptional, and post-translational.
  • Tumor cells manipulate PD-1 expression to suppress anti-cancer immune responses.
  • Targeting PD-1 pathways offers potential for enhancing immunotherapy.

Conclusions:

  • Comprehensive understanding of PD-1 regulation is crucial for advancing cancer immunotherapy.
  • Elucidating these mechanisms can lead to improved T cell function in cancer patients.
  • Further research into PD-1 regulation will enhance therapeutic strategies against cancer.
Keywords:
ImmunotherapyPD-1PD-L1T cell exhaustion

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.0K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.2K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K